OpenLB
Open Library of Bioscience
Advanced Search
Heart failure reviews
Jul, 2024;29 (4): 751-768.

Abnormal phosphorylation / dephosphorylation and Ca dysfunction in heart failure.

Yan-Bing Liu, Qian Wang, Yu-Ling Song, Xiao-Min Song, Yu-Chen Fan, Lin Kong, Jing-Sai Zhang, Sheng Li, Yi-Ju Lv, Ze-Yang Li, Jing-Yu Dai, Zhen-Kang Qiu
Author Information
  1. Yan-Bing Liu: Interventional Medical Center, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong Province, China.
  2. Qian Wang: Medical College, Qingdao University, Qingdao, China.
  3. Yu-Ling Song: Department of Pediatrics, Huantai County Hospital of Traditional Chinese Medicine, Zibo, China.
  4. Xiao-Min Song: Medical College, Qingdao University, Qingdao, China.
  5. Yu-Chen Fan: Medical College, Qingdao University, Qingdao, China.
  6. Lin Kong: Medical College, Qingdao University, Qingdao, China.
  7. Jing-Sai Zhang: Medical College, Qingdao University, Qingdao, China.
  8. Sheng Li: Medical College, Qingdao University, Qingdao, China.
  9. Yi-Ju Lv: Medical College, Qingdao University, Qingdao, China.
  10. Ze-Yang Li: Medical College, Qingdao University, Qingdao, China.
  11. Jing-Yu Dai: Department of Oncology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong Province, China. dr_djy@126.com.
  12. Zhen-Kang Qiu: Interventional Medical Center, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266003, Shandong Province, China. dr_qiuzk@126.com. ORCID
PMID: 38498262 DOI: 10.1007/s10741-024-10395-w

Abstract

Heart failure (HF) can be caused by a variety of causes characterized by abnormal myocardial systole and diastole. Ca current through the L-type calcium channel (LTCC) on the membrane is the initial trigger signal for a cardiac cycle. Declined systole and diastole in HF are associated with dysfunction of myocardial Ca function. This disorder can be correlated with unbalanced levels of phosphorylation / dephosphorylation of LTCC, endoplasmic reticulum (ER), and myofilament. Kinase and phosphatase activity changes along with HF progress, resulting in phased changes in the degree of phosphorylation / dephosphorylation. It is important to realize the phosphorylation / dephosphorylation differences between a normal and a failing heart. This review focuses on phosphorylation / dephosphorylation changes in the progression of HF and summarizes the effects of phosphorylation / dephosphorylation of LTCC, ER function, and myofilament function in normal conditions and HF based on previous experiments and clinical research. Also, we summarize current therapeutic methods based on abnormal phosphorylation / dephosphorylation and clarify potential therapeutic directions.

Keywords

Ca2+ Endoplasmic reticulum Heart failure L-type calcium channel Phosphorylation

References

  1. Katz AM, Rolett EL (2016) Heart failure: when form fails to follow function. Eur Heart J 37(5):449–454. https://doi.org/10.1093/eurheartj/ehv548 [DOI: 10.1093/eurheartj/ehv548]
  2. Wu S, Chen L, Zhou X (2022) Circular RNAs in the regulation of cardiac hypertrophy. Mol Ther Nucleic Acids 27:484–490. https://doi.org/10.1016/j.omtn.2021.12.025 [DOI: 10.1016/j.omtn.2021.12.025]
  3. Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89(9):1401–1438. https://doi.org/10.1007/s00204-015-1477-x [DOI: 10.1007/s00204-015-1477-x]
  4. Liu Y, Chen J, Fontes SK, Bautista EN, Cheng Z (2022) Physiological and pathological roles of protein kinase A in the heart. Cardiovasc Res 118(2):386–398. https://doi.org/10.1093/cvr/cvab008 [DOI: 10.1093/cvr/cvab008]
  5. Wang J, Gareri C, Rockman HA (2018) G-Protein-coupled receptors in heart disease. Circ Res 123(6):716–735. https://doi.org/10.1161/CIRCRESAHA.118.311403 [DOI: 10.1161/CIRCRESAHA.118.311403]
  6. Antos CL, Frey N, Marx SO et al (2001) Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89(11):997–1004. https://doi.org/10.1161/hh2301.100003 [DOI: 10.1161/hh2301.100003]
  7. Bowling N, Walsh RA, Song G et al (1999) Increased protein kinase C activity and expression of Ca-sensitive isoforms in the failing human heart. Circulation 99(3):384–391. https://doi.org/10.1161/01.cir.99.3.384 [DOI: 10.1161/01.cir.99.3.384]
  8. Liu Q, Chen X, Macdonnell SM et al (2009) Protein kinase calpha, but not PKCbeta or PKCgamma, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res 105(2):194–200. https://doi.org/10.1161/CIRCRESAHA.109.195313 [DOI: 10.1161/CIRCRESAHA.109.195313]
  9. Bossuyt J, Helmstadter K, Wu X et al (2008) Ca/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res 102(6):695–702. https://doi.org/10.1161/CIRCRESAHA.107.169755 [DOI: 10.1161/CIRCRESAHA.107.169755]
  10. Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271. https://doi.org/10.1016/j.jacc.2013.02.092 [DOI: 10.1016/j.jacc.2013.02.092]
  11. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934. https://doi.org/10.1126/science.1075762 [DOI: 10.1126/science.1075762]
  12. Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, Vittone L, Kranias E (2005) Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc Res 68(3):366–375. https://doi.org/10.1016/j.cardiores.2005.08.010 [DOI: 10.1016/j.cardiores.2005.08.010]
  13. Haworth RS, Roberts NA, Cuello F, Avkiran M (2007) Regulation of protein kinase D activity in adult myocardium: novel counter-regulatory roles for protein kinase cepsilon and protein kinase A. J Mol Cell Cardiol 43(6):686–695. https://doi.org/10.1016/j.yjmcc.2007.09.013 [DOI: 10.1016/j.yjmcc.2007.09.013]
  14. Kamel R, Leroy J, Vandecasteele G, Fischmeister R (2023) Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nat Rev Cardiol 20(2):90–108. https://doi.org/10.1038/s41569-022-00756-z [DOI: 10.1038/s41569-022-00756-z]
  15. Reyes Gaido OE, Nkashama LJ, Schole KL et al (2023) CaMKII as a therapeutic target in cardiovascular disease. Annu Rev Pharmacol Toxicol 63:249–272. https://doi.org/10.1146/annurev-pharmtox-051421-111814 [DOI: 10.1146/annurev-pharmtox-051421-111814]
  16. Steenaart NA, Ganim JR, Di Salvo J, Kranias EG (1992) The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch Biochem Biophys 293(1):17–24. https://doi.org/10.1016/0003-9861(92)90359-5 [DOI: 10.1016/0003-9861(92)90359-5]
  17. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN (2003) Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285(6):H2373–H2381. https://doi.org/10.1152/ajpheart.00442.2003 [DOI: 10.1152/ajpheart.00442.2003]
  18. Yamada M, Ikeda Y, Yano M et al (2006) Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 20(8):1197–1199. https://doi.org/10.1096/fj.05-5299fje [DOI: 10.1096/fj.05-5299fje]
  19. Lei M, Wang X, Ke Y, Solaro RJ (2015) Regulation of Ca transient by PP2A in normal and failing heart. Front Physiol 6:13. https://doi.org/10.3389/fphys.2015.00013 [DOI: 10.3389/fphys.2015.00013]
  20. Beca S, Ahmad F, Shen W et al (2013) Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res 112(2):289–297. https://doi.org/10.1161/CIRCRESAHA.111.300003 [DOI: 10.1161/CIRCRESAHA.111.300003]
  21. Beca S, Helli PB, Simpson JA et al (2011) Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca release and cardiac contractility, independently of L-type Ca current. Circ Res 109(9):1024–1030. https://doi.org/10.1161/CIRCRESAHA.111.250464 [DOI: 10.1161/CIRCRESAHA.111.250464]
  22. Lehnart SE, Wehrens XH, Reiken S et al (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123(1):25–35. https://doi.org/10.1016/j.cell.2005.07.030 [DOI: 10.1016/j.cell.2005.07.030]
  23. Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S, Rousseau E (1999) Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472(3):431–446. https://doi.org/10.1016/s0304-4165(99)00145-2 [DOI: 10.1016/s0304-4165(99)00145-2]
  24. Kranias EG, Solaro RJ (1982) Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature 298(5870):182–184. https://doi.org/10.1038/298182a0 [DOI: 10.1038/298182a0]
  25. Layland J, Solaro RJ, Shah AM (2005) Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66(1):12–21. https://doi.org/10.1016/j.cardiores.2004.12.022 [DOI: 10.1016/j.cardiores.2004.12.022]
  26. Pena JR, Wolska BM (2004) Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts. Cardiovasc Res 61(4):756–763. https://doi.org/10.1016/j.cardiores.2003.12.019 [DOI: 10.1016/j.cardiores.2003.12.019]
  27. Salhi HE, Walton SD, Hassel NC et al (2014) Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca sensitivity and accelerates deactivation. J Mol Cell Cardiol 76:257–264. https://doi.org/10.1016/j.yjmcc.2014.09.013 [DOI: 10.1016/j.yjmcc.2014.09.013]
  28. Noland TA Jr, Raynor RL, Kuo JF (1989) Identification of sites phosphorylated in bovine cardiac troponin I and troponin T by protein kinase C and comparative substrate activity of synthetic peptides containing the phosphorylation sites. J Biol Chem 264(34):20778–20785 [DOI: 10.1016/S0021-9258(19)47130-5]
  29. Jideama NM, Noland TA Jr, Raynor RL et al (1996) Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem 271(38):23277–23283. https://doi.org/10.1074/jbc.271.38.23277 [DOI: 10.1074/jbc.271.38.23277]
  30. Swiderek K, Jaquet K, Meyer HE, Schachtele C, Hofmann F, Heilmeyer LM Jr (1990) Sites phosphorylated in bovine cardiac troponin T and I. characterization by 31P-NMR spectroscopy and phosphorylation by protein kinases. Eur J Biochem 190(3):575–582. https://doi.org/10.1111/j.1432-1033.1990.tb15612.x [DOI: 10.1111/j.1432-1033.1990.tb15612.x]
  31. Papa A, Kushner J, Marx SO (2022) Adrenergic regulation of calcium channels in the heart. Annu Rev Physiol 84:285–306. https://doi.org/10.1146/annurev-physiol-060121-041653 [DOI: 10.1146/annurev-physiol-060121-041653]
  32. Li L, Cai H, Liu H, Guo T (2015) Beta-adrenergic stimulation activates protein kinase cepsilon and induces extracellular signal-regulated kinase phosphorylation and cardiomyocyte hypertrophy. Mol Med Rep 11(6):4373–4380. https://doi.org/10.3892/mmr.2015.3316 [DOI: 10.3892/mmr.2015.3316]
  33. Oestreich EA, Malik S, Goonasekera SA et al (2009) Epac and phospholipase cepsilon regulate Ca release in the heart by activation of protein kinase cepsilon and calcium-calmodulin kinase II. J Biol Chem 284(3):1514–1522. https://doi.org/10.1074/jbc.M806994200 [DOI: 10.1074/jbc.M806994200]
  34. Sjaastad I, Schiander I, Sjetnan A et al (2003) Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 177(4):449–458. https://doi.org/10.1046/j.1365-201X.2003.01063.x [DOI: 10.1046/j.1365-201X.2003.01063.x]
  35. Suematsu N, Satoh S, Kinugawa S et al (2001) Alpha1-adrenoceptor-Gq-RhoA signaling is upregulated to increase myofibrillar Ca sensitivity in failing hearts. Am J Physiol Heart Circ Physiol 281(2):H637–H646. https://doi.org/10.1152/ajpheart.2001.281.2.H637 [DOI: 10.1152/ajpheart.2001.281.2.H637]
  36. Hussain RI, Qvigstad E, Birkeland JA et al (2009) Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation. Br J Pharmacol 156(4):575–586. https://doi.org/10.1111/j.1750-3639.2009.00016.x [DOI: 10.1111/j.1750-3639.2009.00016.x]
  37. Yamakage M, Namiki A (2002) Calcium channels–basic aspects of their structure, function and gene encoding: anesthetic action on the channels–a review. Can J Anaesth 49(2):151–164. https://doi.org/10.1007/BF03020488 [DOI: 10.1007/BF03020488]
  38. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415(6868):198–205. https://doi.org/10.1038/415198a [DOI: 10.1038/415198a]
  39. Richard S, Perrier E, Fauconnier J et al (2006) Ca-induced Ca entry’ or how the L-type Ca channel remodels its own signalling pathway in cardiac cells. Prog Biophys Mol Biol 90(1–3):118–135. https://doi.org/10.1016/j.pbiomolbio.2005.05.005 [DOI: 10.1016/j.pbiomolbio.2005.05.005]
  40. Bers DM, Despa S (2006) Cardiac myocytes Ca and Na+ regulation in normal and failing hearts. J Pharmacol Sci 100(5):315–322. https://doi.org/10.1254/jphs.cpj06001x [DOI: 10.1254/jphs.cpj06001x]
  41. Kamp TJ, Hell JW (2000) Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 87(12):1095–1102. https://doi.org/10.1161/01.res.87.12.1095 [DOI: 10.1161/01.res.87.12.1095]
  42. Jurevicius J, Fischmeister R (1996) cAMP compartmentation is responsible for a local activation of cardiac Ca channels by beta-adrenergic agonists. Proc Natl Acad Sci USA 93(1):295–299. https://doi.org/10.1073/pnas.93.1.295 [DOI: 10.1073/pnas.93.1.295]
  43. Lindegger N, Niggli E (2005) Paradoxical SR Ca release in guinea-pig cardiac myocytes after beta-adrenergic stimulation revealed by two-photon photolysis of caged Ca. J Physiol 565(Pt 3):801–813. https://doi.org/10.1113/jphysiol.2005.084376 [DOI: 10.1113/jphysiol.2005.084376]
  44. Mery PF, Abi-Gerges N, Vandecasteele G, Jurevicius J, Eschenhagen T, Fischmeister R (1997) Muscarinic regulation of the L-type calcium current in isolated cardiac myocytes. Life Sci 60(13–14):1113–1120. https://doi.org/10.1016/s0024-3205(97)00055-6 [DOI: 10.1016/s0024-3205(97)00055-6]
  45. Fischmeister R, Castro LR, Abi-Gerges A et al (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99(8):816–828. https://doi.org/10.1161/01.RES.0000246118.98832.04 [DOI: 10.1161/01.RES.0000246118.98832.04]
  46. Alden KJ, Goldspink PH, Ruch SW, Buttrick PM, Garcia J (2002) Enhancement of L-type Ca current from neonatal mouse ventricular myocytes by constitutively active PKC-betaII. Am J Physiol Cell Physiol 282(4):C768–774. https://doi.org/10.1152/ajpcell.00494.2001 [DOI: 10.1152/ajpcell.00494.2001]
  47. Yue Y, Qu Y, Boutjdir M (2004) Beta- and alpha-adrenergic cross-signaling for L-type ca current is impaired in transgenic mice with constitutive activation of epsilon PKC. Biochem Biophys Res Commun 314(3):749–754. https://doi.org/10.1016/j.bbrc.2003.12.155 [DOI: 10.1016/j.bbrc.2003.12.155]
  48. Gomez AM, Valdivia HH, Cheng H et al (1997) Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276(5313):800–806. https://doi.org/10.1126/science.276.5313.800 [DOI: 10.1126/science.276.5313.800]
  49. Ouadid H, Albat B, Nargeot J (1995) Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 25(2):282–291. https://doi.org/10.1097/00005344-199502000-00014 [DOI: 10.1097/00005344-199502000-00014]
  50. Davare MA, Horne MC, Hell JW (2000) Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase. J Biol Chem 275(50):39710–39717. https://doi.org/10.1074/jbc.M005462200 [DOI: 10.1074/jbc.M005462200]
  51. Ganesan AN, Maack C, Johns DC, Sidor A, O’Rourke B (2006) Beta-adrenergic stimulation of L-type Ca channels in cardiac myocytes requires the distal carboxyl terminus of alpha1C but not serine 1928. Circ Res 98(2):e11–18. https://doi.org/10.1161/01.RES.0000202692.23001.e2 [DOI: 10.1161/01.RES.0000202692.23001.e2]
  52. Yang L, Katchman A, Samad T, Morrow J, Weinberg R, Marx SO (2013) Beta-adrenergic regulation of the L-type Ca channel does not require phosphorylation of alpha1C Ser1700. Circ Res 113(7):871–880. https://doi.org/10.1161/CIRCRESAHA.113.301926 [DOI: 10.1161/CIRCRESAHA.113.301926]
  53. Fu Y, Westenbroek RE, Scheuer T, Catterall WA (2014) Basal and beta-adrenergic regulation of the cardiac calcium channel CaV1.2 requires phosphorylation of serine 1700. Proc Natl Acad Sci USA 111(46):16598–16603. https://doi.org/10.1073/pnas.1419129111 [DOI: 10.1073/pnas.1419129111]
  54. Yang L, Dai DF, Yuan C et al (2016) Loss of beta-adrenergic-stimulated phosphorylation of CaV1.2 channels on Ser1700 leads to heart failure. Proc Natl Acad Sci USA 113(49):E7976–E7985. https://doi.org/10.1073/pnas.1617116113 [DOI: 10.1073/pnas.1617116113]
  55. Katchman A, Yang L, Zakharov SI et al (2017) Proteolytic cleavage and PKA phosphorylation of alpha(1 C) subunit are not required for adrenergic regulation of ca(V)1.2 in the heart. Proc Natl Acad Sci USA 114(34):9194–9199. https://doi.org/10.1073/pnas.1706054114 [DOI: 10.1073/pnas.1706054114]
  56. Hulme JT, Lin TW, Westenbroek RE, Scheuer T, Catterall WA (2003) Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with a kinase-anchoring protein 15. Proc Natl Acad Sci USA 100(22):13093–13098. https://doi.org/10.1073/pnas.2135335100 [DOI: 10.1073/pnas.2135335100]
  57. Hall DD, Davare MA, Shi M et al (2007) Critical role of cAMP-dependent protein kinase anchoring to the L-type calcium channel Cav1.2 via A-kinase anchor protein 150 in neurons. Biochemistry 46(6):1635–1646. https://doi.org/10.1021/bi062217x [DOI: 10.1021/bi062217x]
  58. Michalak M, Opas M (2009) Endoplasmic and sarcoplasmic reticulum in the heart. Trends Cell Biol 19(6):253–259. https://doi.org/10.1016/j.tcb.2009.03.006 [DOI: 10.1016/j.tcb.2009.03.006]
  59. Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101(4):365–376. https://doi.org/10.1016/s0092-8674(00)80847-8 [DOI: 10.1016/s0092-8674(00)80847-8]
  60. Brillantes AB, Ondrias K, Scott A et al (1994) Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 77(4):513–523. https://doi.org/10.1016/0092-8674(94)90214-3 [DOI: 10.1016/0092-8674(94)90214-3]
  61. Marx SO, Ondrias K, Marks AR (1998) Coupled gating between individual skeletal muscle Ca release channels (ryanodine receptors). Science 281(5378):818–821. https://doi.org/10.1126/science.281.5378.818 [DOI: 10.1126/science.281.5378.818]
  62. Kaftan E, Marks AR, Ehrlich BE (1996) Effects of rapamycin on ryanodine receptor/Ca-release channels from cardiac muscle. Circ Res 78(6):990–997. https://doi.org/10.1161/01.res.78.6.990 [DOI: 10.1161/01.res.78.6.990]
  63. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM (2005) Ca/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca leak in heart failure. Circ Res 97(12):1314–1322. https://doi.org/10.1161/01.RES.0000194329.41863.89 [DOI: 10.1161/01.RES.0000194329.41863.89]
  64. Walweel K, Molenaar P, Imtiaz MS et al (2017) Ryanodine receptor modification and regulation by intracellular Ca and Mg in healthy and failing human hearts. J Mol Cell Cardiol 104:53–62. https://doi.org/10.1016/j.yjmcc.2017.01.016 [DOI: 10.1016/j.yjmcc.2017.01.016]
  65. MacDonnell SM, Garcia-Rivas G, Scherman JA et al (2008) Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. Circ Res 102(8):e65–e72. https://doi.org/10.1161/CIRCRESAHA.108.174722 [DOI: 10.1161/CIRCRESAHA.108.174722]
  66. Alvarado FJ, Chen X, Valdivia HH (2017) Ablation of the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic response or the progression to heart failure in mice. Elimination of the genetic background as critical variable. J Mol Cell Cardiol 103:40–47. https://doi.org/10.1016/j.yjmcc.2017.01.001 [DOI: 10.1016/j.yjmcc.2017.01.001]
  67. Fischer TH, Herting J, Tirilomis T et al (2013) Ca/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca leak in human cardiac pathology. Circulation 128(9):970–981. https://doi.org/10.1161/CIRCULATIONAHA.113.001746 [DOI: 10.1161/CIRCULATIONAHA.113.001746]
  68. Periasamy M, Bhupathy P, Babu GJ (2008) Regulation of sarcoplasmic reticulum Ca ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res 77(2):265–273. https://doi.org/10.1093/cvr/cvm056 [DOI: 10.1093/cvr/cvm056]
  69. MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4(7):566–577. https://doi.org/10.1038/nrm1151 [DOI: 10.1038/nrm1151]
  70. Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78(4):921–947. https://doi.org/10.1152/physrev.1998.78.4.921 [DOI: 10.1152/physrev.1998.78.4.921]
  71. Brittsan AG, Kranias EG (2000) Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32(12):2131–2139. https://doi.org/10.1006/jmcc.2000.1270 [DOI: 10.1006/jmcc.2000.1270]
  72. Tada M (1992) Molecular structure and function of phospholamban in regulating the calcium pump from sarcoplasmic reticulum. Ann NY Acad Sci 671:92–102 discussion 102–103. https://doi.org/10.1111/j.1749-6632.1992.tb43787.x [DOI: 10.1111/j.1749-6632.1992.tb43787.x]
  73. Tada M, Inui M (1983) Regulation of calcium transport by the ATPase-phospholamban system. J Mol Cell Cardiol 15(9):565–575. https://doi.org/10.1016/0022-2828(83)90267-5 [DOI: 10.1016/0022-2828(83)90267-5]
  74. Tada M, Ohmori F, Kinoshita N, Abe H (1978) Cyclic AMP regulation of active calcium transport across membranes of sarcoplasmic reticulum: role of the 22,000-dalton protein phospholamban. Adv Cycl Nucleotide Res 9:355–369
  75. Kadambi VJ, Kranias EG (1997) Phospholamban: a protein coming of age. Biochem Biophys Res Commun 239(1):1–5. https://doi.org/10.1006/bbrc.1997.7340 [DOI: 10.1006/bbrc.1997.7340]
  76. Koss KL, Kranias EG (1996) Phospholamban: a prominent regulator of myocardial contractility. Circ Res 79(6):1059–1063. https://doi.org/10.1161/01.res.79.6.1059 [DOI: 10.1161/01.res.79.6.1059]
  77. Wegener AD, Simmerman HK, Lindemann JP, Jones LR (1989) Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 264(19):11468–11474 [DOI: 10.1016/S0021-9258(18)60487-9]
  78. Talosi L, Edes I, Kranias EG (1993) Intracellular mechanisms mediating reversal of beta-adrenergic stimulation in intact beating hearts. Am J Physiol 264(3 Pt 2):H791–H797. https://doi.org/10.1152/ajpheart.1993.264.3.H791 [DOI: 10.1152/ajpheart.1993.264.3.H791]
  79. Lindemann JP, Jones LR, Hathaway DR, Henry BG, Watanabe AM (1983) Beta-adrenergic stimulation of phospholamban phosphorylation and Ca-ATPase activity in guinea pig ventricles. J Biol Chem 258(1):464–471 [DOI: 10.1016/S0021-9258(18)33279-4]
  80. Garvey JL, Kranias EG, Solaro RJ (1988) Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem J 249(3):709–714. https://doi.org/10.1042/bj2490709 [DOI: 10.1042/bj2490709]
  81. Mundina-Weilenmann C, Vittone L, Ortale M, de Cingolani GC, Mattiazzi A (1996) Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J Biol Chem 271(52):33561–33567. https://doi.org/10.1074/jbc.271.52.33561 [DOI: 10.1074/jbc.271.52.33561]
  82. Sande JB, Sjaastad I, Hoen IB et al (2002) Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 53(2):382–391. https://doi.org/10.1016/s0008-6363(01)00489-8 [DOI: 10.1016/s0008-6363(01)00489-8]
  83. Currie S, Smith GL (1999) Enhanced phosphorylation of phospholamban and downregulation of sarco/endoplasmic reticulum Ca ATPase type 2 (SERCA 2) in cardiac sarcoplasmic reticulum from rabbits with heart failure. Cardiovasc Res 41(1):135–146. https://doi.org/10.1016/s0008-6363(98)00241-7 [DOI: 10.1016/s0008-6363(98)00241-7]
  84. Boknik P, Heinroth-Hoffmann I, Kirchhefer U et al (2001) Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovasc Res 51(4):717–728. https://doi.org/10.1016/s0008-6363(01)00346-7 [DOI: 10.1016/s0008-6363(01)00346-7]
  85. Mills GD, Kubo H, Harris DM, Berretta RM, Piacentino V 3rd, Houser SR (2006) Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol 291(1):H61–H70. https://doi.org/10.1152/ajpheart.01353.2005 [DOI: 10.1152/ajpheart.01353.2005]
  86. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E (1999) Reduced Ca-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31(3):479–491. https://doi.org/10.1006/jmcc.1998.0897 [DOI: 10.1006/jmcc.1998.0897]
  87. Aoyama H, Ikeda Y, Miyazaki Y et al (2011) Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca cycling. Cardiovasc Res 89(1):79–88. https://doi.org/10.1093/cvr/cvq252 [DOI: 10.1093/cvr/cvq252]
  88. van der Velden J, Papp Z, Zaremba R et al (2003) Increased Ca-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 57(1):37–47. https://doi.org/10.1016/s0008-6363(02)00606-5 [DOI: 10.1016/s0008-6363(02)00606-5]
  89. Pulcastro HC, Awinda PO, Breithaupt JJ, Tanner BC (2016) Effects of myosin light chain phosphorylation on length-dependent myosin kinetics in skinned rat myocardium. Arch Biochem Biophys 601:56–68. https://doi.org/10.1016/j.abb.2015.12.014 [DOI: 10.1016/j.abb.2015.12.014]
  90. Kampourakis T, Sun YB, Irving M (2016) Myosin light chain phosphorylation enhances contraction of heart muscle via structural changes in both thick and thin filaments. Proc Natl Acad Sci USA 113(21):E3039–E3047. https://doi.org/10.1073/pnas.1602776113 [DOI: 10.1073/pnas.1602776113]
  91. Markandran K, Yu H, Song W, Lam D, Madathummal MC, Ferenczi MA (2021) Functional and molecular characterisation of heart failure progression in mice and the role of myosin regulatory light chains in the recovery of cardiac muscle function. Int J Mol Sci 23(1):88. https://doi.org/10.3390/ijms23010088 [DOI: 10.3390/ijms23010088]
  92. Jacques AM, Copeland O, Messer AE et al (2008) Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. J Mol Cell Cardiol 45(2):209–216. https://doi.org/10.1016/j.yjmcc.2008.05.020 [DOI: 10.1016/j.yjmcc.2008.05.020]
  93. Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL (2008) Acceleration of crossbridge kinetics by protein kinase a phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ Res 103(9):974–982. https://doi.org/10.1161/CIRCRESAHA.108.177683 [DOI: 10.1161/CIRCRESAHA.108.177683]
  94. Gilda JE, Gomes AV (2013) How phosphorylated can it get? Cardiac myosin binding protein C phosphorylation in heart failure. J Mol Cell Cardiol 62:108–110. https://doi.org/10.1016/j.yjmcc.2013.05.015 [DOI: 10.1016/j.yjmcc.2013.05.015]
  95. Gresham KS, Stelzer JE (2016) The contributions of cardiac myosin binding protein C and troponin I phosphorylation to beta-adrenergic enhancement of in vivo cardiac function. J Physiol 594(3):669–686. https://doi.org/10.1113/JP270959 [DOI: 10.1113/JP270959]
  96. McNamara JW, Singh RR, Sadayappan S (2019) Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin. Proc Natl Acad Sci USA 116(24):11731–11736. https://doi.org/10.1073/pnas.1821660116 [DOI: 10.1073/pnas.1821660116]
  97. Messer AE, Jacques AM, Marston SB (2007) Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 42(1):247–259. https://doi.org/10.1016/j.yjmcc.2006.08.017 [DOI: 10.1016/j.yjmcc.2006.08.017]
  98. Konhilas JP, Irving TC, Wolska BM et al (2003) Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing. J Physiol 547(Pt 3):951–961. https://doi.org/10.1113/jphysiol.2002.038117 [DOI: 10.1113/jphysiol.2002.038117]
  99. Horn K, Leontieva L, Williams JM, Furbee PM, Helmkamp JC, Manley WG 3rd (2002) Alcohol problems among young adult emergency department patients: making predictions using routine sociodemographic information. J Crit Care 17(4):212–220. https://doi.org/10.1053/jcrc.2002.37231 [DOI: 10.1053/jcrc.2002.37231]
  100. Zhang P, Kirk JA, Ji W et al (2012) Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation 126(15):1828–1837. https://doi.org/10.1161/CIRCULATIONAHA.112.096388 [DOI: 10.1161/CIRCULATIONAHA.112.096388]
  101. Wijnker PJ, Sequeira V, Witjas-Paalberends ER et al (2014) Phosphorylation of protein kinase C sites Ser42/44 decreases Ca-sensitivity and blunts enhanced length-dependent activation in response to protein kinase A in human cardiomyocytes. Arch Biochem Biophys 554:11–21. https://doi.org/10.1016/j.abb.2014.04.017 [DOI: 10.1016/j.abb.2014.04.017]
  102. Wijnker PJ, Foster DB, Tsao AL et al (2013) Impact of site-specific phosphorylation of protein kinase A sites Ser23 and Ser24 of cardiac troponin I in human cardiomyocytes. Am J Physiol Heart Circ Physiol 304(2):H260–H268. https://doi.org/10.1152/ajpheart.00498.2012 [DOI: 10.1152/ajpheart.00498.2012]
  103. Martin-Garrido A, Biesiadecki BJ, Salhi HE et al (2018) Monophosphorylation of cardiac troponin-I at Ser-23/24 is sufficient to regulate cardiac myofibrillar Ca sensitivity and calpain-induced proteolysis. J Biol Chem 293(22):8588–8599. https://doi.org/10.1074/jbc.RA117.001292 [DOI: 10.1074/jbc.RA117.001292]
  104. Ravichandran VS, Patel HJ, Pagani FD, Westfall MV (2019) Cardiac contractile dysfunction and protein kinase C-mediated myofilament phosphorylation in disease and aging. J Gen Physiol 151(9):1070–1080. https://doi.org/10.1085/jgp.201912353 [DOI: 10.1085/jgp.201912353]
  105. Nixon BR, Walton SD, Zhang B et al (2014) Combined troponin I Ser-150 and Ser-23/24 phosphorylation sustains thin filament Ca sensitivity and accelerates deactivation in an acidic environment. J Mol Cell Cardiol 72:177–185. https://doi.org/10.1016/j.yjmcc.2014.03.010 [DOI: 10.1016/j.yjmcc.2014.03.010]
  106. Salhi HE, Hassel NC, Siddiqui JK et al (2016) Myofilament calcium sensitivity: mechanistic insight into TnI Ser-23/24 and Ser-150 phosphorylation integration. Front Physiol 7:567. https://doi.org/10.3389/fphys.2016.00567 [DOI: 10.3389/fphys.2016.00567]
  107. Kooij V, Zhang P, Piersma SR et al (2013) PKCalpha-specific phosphorylation of the troponin complex in human myocardium: a functional and proteomics analysis. PLoS ONE 8(10):e74847. https://doi.org/10.1371/journal.pone.0074847 [DOI: 10.1371/journal.pone.0074847]
  108. Fugger L, Morling N, Bendtzen K et al (1989) IL-6 gene polymorphism in rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, systemic lupus erythematosus, and in healthy Danes. J Immunogenet 16(6):461–465. https://doi.org/10.1111/j.1744-313x.1989.tb00495.x [DOI: 10.1111/j.1744-313x.1989.tb00495.x]
  109. Wijnker PJ, Sequeira V, Foster DB et al (2014) Length-dependent activation is modulated by cardiac troponin I bisphosphorylation at Ser23 and Ser24 but not by Thr143 phosphorylation. Am J Physiol Heart Circ Physiol 306(8):H1171–H1181. https://doi.org/10.1152/ajpheart.00580.2013 [DOI: 10.1152/ajpheart.00580.2013]
  110. Kooij V, Boontje N, Zaremba R et al (2010) Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca sensitivity in human myocardium. Basic Res Cardiol 105(2):289–300. https://doi.org/10.1007/s00395-009-0053-z [DOI: 10.1007/s00395-009-0053-z]
  111. Solaro RJ, Kobayashi T (2011) Protein phosphorylation and signal transduction in cardiac thin filaments. J Biol Chem 286(12):9935–9940. https://doi.org/10.1074/jbc.R110.197731 [DOI: 10.1074/jbc.R110.197731]
  112. Linke WA, Hamdani N (2014) Gigantic business: titin properties and function through thick and thin. Circ Res 114(6):1052–1068. https://doi.org/10.1161/CIRCRESAHA.114.301286 [DOI: 10.1161/CIRCRESAHA.114.301286]
  113. Leite-Moreira AM, Almeida-Coelho J, Neves JS et al (2018) Stretch-induced compliance: a novel adaptive biological mechanism following acute cardiac load. Cardiovasc Res 114(5):656–667. https://doi.org/10.1093/cvr/cvy026 [DOI: 10.1093/cvr/cvy026]
  114. Gomori K, Herwig M, Budde H et al (2022) Ca/calmodulin-dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model. ESC Heart Fail 9(4):2585–2600. https://doi.org/10.1002/ehf2.13973 [DOI: 10.1002/ehf2.13973]
  115. Mohamed BA, Schnelle M, Khadjeh S et al (2016) Molecular and structural transition mechanisms in long-term volume overload. Eur J Heart Fail 18(4):362–371. https://doi.org/10.1002/ejhf.465 [DOI: 10.1002/ejhf.465]
  116. Hofmann F, Wegener JW (2013) cGMP-dependent protein kinases (cGK). Methods Mol Biol 1020:17–50. https://doi.org/10.1007/978-1-62703-459-3_2 [DOI: 10.1007/978-1-62703-459-3_2]
  117. Kovacs A, Herwig M, Budde H et al (2021) Interventricular differences of signaling pathways-mediated regulation of cardiomyocyte function in response to high oxidative stress in the post-ischemic failing rat heart. Antioxid (Basel) 10(6):964. https://doi.org/10.3390/antiox10060964 [DOI: 10.3390/antiox10060964]
  118. Sugimoto M, Murata M, Yamaoka Y (2020) Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an east Asian population: Meta-analysis. World J Gastroenterol 26(15):1820–1840. https://doi.org/10.3748/wjg.v26.i15.1820 [DOI: 10.3748/wjg.v26.i15.1820]
  119. Carr AN, Schmidt AG, Suzuki Y et al (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22(12):4124–4135. https://doi.org/10.1128/MCB.22.12.4124-4135.2002 [DOI: 10.1128/MCB.22.12.4124-4135.2002]
  120. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T (2004) Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61(1):87–93. https://doi.org/10.1016/j.cardiores.2003.11.005 [DOI: 10.1016/j.cardiores.2003.11.005]
  121. Gupta RC, Mishra S, Yang XP, Sabbah HN (2005) Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell Biochem 269(1–2):49–57. https://doi.org/10.1007/s11010-005-2538-x [DOI: 10.1007/s11010-005-2538-x]
  122. Huang FL, Glinsmann WH (1976) Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur J Biochem 70(2):419–426. https://doi.org/10.1111/j.1432-1033.1976.tb11032.x [DOI: 10.1111/j.1432-1033.1976.tb11032.x]
  123. Neumann J, Gupta RC, Schmitz W, Scholz H, Nairn AC, Watanabe AM (1991) Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ Res 69(6):1450–1457. https://doi.org/10.1161/01.res.69.6.1450 [DOI: 10.1161/01.res.69.6.1450]
  124. Iyer RB, Koritz SB, Kirchberger MA (1988) A regulation of the level of phosphorylated phospholamban by inhibitor-1 in rat heart preparations in vitro. Mol Cell Endocrinol 55(1):1–6. https://doi.org/10.1016/0303-7207(88)90084-6 [DOI: 10.1016/0303-7207(88)90084-6]
  125. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol 270(Pt 2):H1159–1164. https://doi.org/10.1152/ajpheart.1996.270.4.H1159 [DOI: 10.1152/ajpheart.1996.270.4.H1159]
  126. El-Armouche A, Bednorz A, Pamminger T et al (2006) Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun 346(3):700–706. https://doi.org/10.1016/j.bbrc.2006.05.182 [DOI: 10.1016/j.bbrc.2006.05.182]
  127. Foulkes JG, Strada SJ, Henderson PJ, Cohen P (1983) A kinetic analysis of the effects of inhibitor-1 and inhibitor-2 on the activity of protein phosphatase-1. Eur J Biochem 132(2):309–313. https://doi.org/10.1111/j.1432-1033.1983.tb07363.x [DOI: 10.1111/j.1432-1033.1983.tb07363.x]
  128. Huang KX, Paudel HK (2000) Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor. Proc Natl Acad Sci USA 97(11):5824–5829. https://doi.org/10.1073/pnas.100460897 [DOI: 10.1073/pnas.100460897]
  129. Braz JC, Gregory K, Pathak A et al (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10(3):248–254. https://doi.org/10.1038/nm1000 [DOI: 10.1038/nm1000]
  130. Rodriguez P, Mitton B, Waggoner JR, Kranias EG (2006) Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem 281(50):38599–38608. https://doi.org/10.1074/jbc.M604139200 [DOI: 10.1074/jbc.M604139200]
  131. Park IK, DePaoli-Roach AA (1994) Domains of phosphatase inhibitor-2 involved in the control of the ATP-Mg-dependent protein phosphatase. J Biol Chem 269(46):28919–28928 [DOI: 10.1016/S0021-9258(19)61995-2]
  132. Yang J, Hurley TD, DePaoli-Roach AA (2000) Interaction of inhibitor-2 with the catalytic subunit of type 1 protein phosphatase. Identification of a sequence analogous to the consensus type 1 protein phosphatase-binding motif. J Biol Chem 275(30):22635–22644. https://doi.org/10.1074/jbc.M003082200 [DOI: 10.1074/jbc.M003082200]
  133. Kirchhefer U, Baba HA, Boknik P et al (2005) Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2. Cardiovasc Res 68(1):98–108. https://doi.org/10.1016/j.cardiores.2005.05.019 [DOI: 10.1016/j.cardiores.2005.05.019]
  134. Wehrens XH, Lehnart SE, Reiken SR et al (2004) Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304(5668):292–296. https://doi.org/10.1126/science.1094301 [DOI: 10.1126/science.1094301]
  135. Yano M, Ono K, Ohkusa T et al (2000) Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca leak through ryanodine receptor in heart failure. Circulation 102(17):2131–2136. https://doi.org/10.1161/01.cir.102.17.2131 [DOI: 10.1161/01.cir.102.17.2131]
  136. Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309(12):1268–1277. https://doi.org/10.1001/jama.2013.2024 [DOI: 10.1001/jama.2013.2024]
  137. Miller CL, Oikawa M, Cai Y et al (2009) Role of Ca/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105(10):956–964. https://doi.org/10.1161/CIRCRESAHA.109.198515 [DOI: 10.1161/CIRCRESAHA.109.198515]
  138. Miller CL, Cai Y, Oikawa M et al (2011) Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Res Cardiol 106(6):1023–1039. https://doi.org/10.1007/s00395-011-0228-2 [DOI: 10.1007/s00395-011-0228-2]
  139. Wu MP, Zhang YS, Xu X, Zhou Q, Li JD, Yan C (2017) Vinpocetine attenuates pathological cardiac remodeling by inhibiting Cardiac Hypertrophy and Fibrosis. Cardiovasc Drugs Ther 31(2):157–166. https://doi.org/10.1007/s10557-017-6719-0 [DOI: 10.1007/s10557-017-6719-0]
  140. Hashimoto T, Kim GE, Tunin RS et al (2018) Acute enhancement of cardiac function by phosphodiesterase type 1 inhibition. Circulation 138(18):1974–1987. https://doi.org/10.1161/CIRCULATIONAHA.117.030490 [DOI: 10.1161/CIRCULATIONAHA.117.030490]
  141. Gilotra NA, DeVore AD, Povsic TJ et al (2021) Acute hemodynamic effects and tolerability of phosphodiesterase-1 inhibition with ITI-214 in human systolic heart failure. Circ Heart Fail 14(9):e008236. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008236 [DOI: 10.1161/CIRCHEARTFAILURE.120.008236]
  142. Aye TT, Soni S, van Veen TA et al (2012) Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 52(2):511–518. https://doi.org/10.1016/j.yjmcc.2011.06.003 [DOI: 10.1016/j.yjmcc.2011.06.003]
  143. Mehel H, Emons J, Vettel C et al (2013) Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes. J Am Coll Cardiol 62(17):1596–1606. https://doi.org/10.1016/j.jacc.2013.05.057 [DOI: 10.1016/j.jacc.2013.05.057]
  144. Galindo-Tovar A, Vargas ML, Kaumann AJ (2018) Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce beta-adrenoceptor-mediated chronotropic and inotropic effects in rat heart. Naunyn Schmiedebergs Arch Pharmacol 391(6):571–585. https://doi.org/10.1007/s00210-018-1480-x [DOI: 10.1007/s00210-018-1480-x]
  145. Zoccarato A, Surdo NC, Aronsen JM et al (2015) Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2. Circ Res 117(8):707–719. https://doi.org/10.1161/CIRCRESAHA.114.305892 [DOI: 10.1161/CIRCRESAHA.114.305892]
  146. Baliga RS, Preedy MEJ, Dukinfield MS et al (2018) Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. Proc Natl Acad Sci USA 115(31):E7428–E7437. https://doi.org/10.1073/pnas.1800996115 [DOI: 10.1073/pnas.1800996115]
  147. Vettel C, Lindner M, Dewenter M et al (2017) Phosphodiesterase 2 protects against catecholamine-induced arrhythmia and preserves contractile function after myocardial infarction. Circ Res 120(1):120–132. https://doi.org/10.1161/CIRCRESAHA.116.310069 [DOI: 10.1161/CIRCRESAHA.116.310069]
  148. Wagner M, Sadek MS, Dybkova N et al (2021) Cellular mechanisms of the anti-arrhythmic effect of Cardiac PDE2 overexpression. Int J Mol Sci 22(9):4816. https://doi.org/10.3390/ijms22094816 [DOI: 10.3390/ijms22094816]
  149. Liu K, Li D, Hao G et al (2018) Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity. JCI Insight 3(9):e98694. https://doi.org/10.1172/jci.insight.98694 [DOI: 10.1172/jci.insight.98694]
  150. Barbagallo F, Xu B, Reddy GR et al (2016) Genetically encoded biosensors reveal PKA hyperphosphorylation on the myofilaments in rabbit heart failure. Circ Res 119(8):931–943. https://doi.org/10.1161/CIRCRESAHA.116.308964 [DOI: 10.1161/CIRCRESAHA.116.308964]
  151. Verde I, Pahlke G, Salanova M et al (2001) Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276(14):11189–11198. https://doi.org/10.1074/jbc.M006546200 [DOI: 10.1074/jbc.M006546200]
  152. Dodge-Kafka KL, Soughayer J, Pare GC et al (2005) The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437(7058):574–578. https://doi.org/10.1038/nature03966 [DOI: 10.1038/nature03966]
  153. Dodge KL, Khouangsathiene S, Kapiloff MS et al (2001) mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20(8):1921–1930. https://doi.org/10.1093/emboj/20.8.1921 [DOI: 10.1093/emboj/20.8.1921]
  154. Ahmad F, Shen W, Vandeput F et al (2015) Regulation of sarcoplasmic reticulum Ca ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J Biol Chem 290(11):6763–6776. https://doi.org/10.1074/jbc.M115.638585 [DOI: 10.1074/jbc.M115.638585]
  155. Vandecasteele G, Verde I, Rucker-Martin C, Donzeau-Gouge P, Fischmeister R (2001) Cyclic GMP regulation of the L-type Ca channel current in human atrial myocytes. J Physiol 533(Pt 2):329–340. https://doi.org/10.1111/j.1469-7793.2001.0329a.x [DOI: 10.1111/j.1469-7793.2001.0329a.x]
  156. Leroy J, Abi-Gerges A, Nikolaev VO et al (2008) Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 102(9):1091–1100. https://doi.org/10.1161/CIRCRESAHA.107.167817 [DOI: 10.1161/CIRCRESAHA.107.167817]
  157. Verde I, Vandecasteele G, Lezoualc’h F, Fischmeister R (1999) Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca current in rat ventricular myocytes. Br J Pharmacol 127(1):65–74. https://doi.org/10.1038/sj.bjp.0702506 [DOI: 10.1038/sj.bjp.0702506]
  158. Ono K, Trautwein W (1991) Potentiation by cyclic GMP of beta-adrenergic effect on Ca current in guinea-pig ventricular cells. J Physiol 443:387–404. https://doi.org/10.1113/jphysiol.1991.sp018839 [DOI: 10.1113/jphysiol.1991.sp018839]
  159. Fischmeister R, Hartzell HC (1990) Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells. Mol Pharmacol 38(3):426–433 [PMID: 1698253]
  160. Yano M, Kohno M, Ohkusa T et al (2000) Effect of milrinone on left ventricular relaxation and Ca uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 279(4):H1898–H1905. https://doi.org/10.1152/ajpheart.2000.279.4.H1898 [DOI: 10.1152/ajpheart.2000.279.4.H1898]
  161. Malecot CO, Bers DM, Katzung BG (1986) Biphasic contractions induced by milrinone at low temperature in ferret ventricular muscle: role of the sarcoplasmic reticulum and transmembrane calcium influx. Circ Res 59(2):151–162. https://doi.org/10.1161/01.res.59.2.151 [DOI: 10.1161/01.res.59.2.151]
  162. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmic reticulum-associated cyclic adenosine 5’-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88(1):15–19. https://doi.org/10.1172/JCI115272 [DOI: 10.1172/JCI115272]
  163. von der Leyen H, Mende U, Meyer W et al (1991) Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol 344(1):90–100. https://doi.org/10.1007/BF00167387 [DOI: 10.1007/BF00167387]
  164. Ding B, Abe JI, Wei H et al (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111(19):2469–2476. https://doi.org/10.1161/01.CIR.0000165128.39715.87 [DOI: 10.1161/01.CIR.0000165128.39715.87]
  165. Mika D, Bobin P, Lindner M et al (2019) Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model. J Mol Cell Cardiol 133:57–66. https://doi.org/10.1016/j.yjmcc.2019.05.025 [DOI: 10.1016/j.yjmcc.2019.05.025]
  166. Abi-Gerges A, Richter W, Lefebvre F et al (2009) Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res 105(8):784–792. https://doi.org/10.1161/CIRCRESAHA.109.197947 [DOI: 10.1161/CIRCRESAHA.109.197947]
  167. Ding B, Abe J, Wei H et al (2005) A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102(41):14771–14776. https://doi.org/10.1073/pnas.0506489102 [DOI: 10.1073/pnas.0506489102]
  168. Smith CJ, He J, Ricketts SG, Ding JZ, Moggio RA, Hintze TH (1998) Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. Cell Biochem Biophys 29(1–2):67–88. https://doi.org/10.1007/BF02737829 [DOI: 10.1007/BF02737829]
  169. Smith CJ, Huang R, Sun D et al (1997) Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96(9):3116–3123. https://doi.org/10.1161/01.cir.96.9.3116 [DOI: 10.1161/01.cir.96.9.3116]
  170. Hanna R, Nour-Eldine W, Saliba Y et al (2021) Cardiac phosphodiesterases are differentially increased in diabetic cardiomyopathy. Life Sci 283:119857. https://doi.org/10.1016/j.lfs.2021.119857 [DOI: 10.1016/j.lfs.2021.119857]
  171. Polidovitch N, Yang S, Sun H et al (2019) Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload. J Mol Cell Cardiol 132:60–70. https://doi.org/10.1016/j.yjmcc.2019.04.028 [DOI: 10.1016/j.yjmcc.2019.04.028]
  172. Li EA, Xi W, Han YS, Brozovich FV (2019) Phosphodiesterase expression in the normal and failing heart. Arch Biochem Biophys 662:160–168. https://doi.org/10.1016/j.abb.2018.12.013 [DOI: 10.1016/j.abb.2018.12.013]
  173. Takahashi K, Osanai T, Nakano T, Wakui M, Okumura K (2002) Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure. Heart Vessels 16(6):249–256. https://doi.org/10.1007/s003800200032 [DOI: 10.1007/s003800200032]
  174. Holmes JR, Kubo SH, Cody RJ, Kligfield P (1985) Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. Am Heart J 110(4):800–806. https://doi.org/10.1016/0002-8703(85)90460-0 [DOI: 10.1016/0002-8703(85)90460-0]
  175. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320(11):677–683. https://doi.org/10.1056/NEJM198903163201101 [DOI: 10.1056/NEJM198903163201101]
  176. Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB (2000) UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem 275(14):10349–10358. https://doi.org/10.1074/jbc.275.14.10349 [DOI: 10.1074/jbc.275.14.10349]
  177. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18(4):893–903. https://doi.org/10.1093/emboj/18.4.893 [DOI: 10.1093/emboj/18.4.893]
  178. Mika D, Bobin P, Pomerance M et al (2013) Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes. Cardiovasc Res 100(2):336–346. https://doi.org/10.1093/cvr/cvt193 [DOI: 10.1093/cvr/cvt193]
  179. Abi-Gerges A, Castro L, Leroy J, Domergue V, Fischmeister R, Vandecasteele G (2021) Selective changes in cytosolic beta-adrenergic cAMP signals and L-type calcium channel regulation by phosphodiesterases during cardiac hypertrophy. J Mol Cell Cardiol 150:109–121. https://doi.org/10.1016/j.yjmcc.2020.10.011 [DOI: 10.1016/j.yjmcc.2020.10.011]
  180. Qvigstad E, Moltzau LR, Aronsen JM et al (2010) Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 85(4):763–772. https://doi.org/10.1093/cvr/cvp364 [DOI: 10.1093/cvr/cvp364]
  181. Minamisawa S, Hoshijima M, Chu G et al (1999) Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99(3):313–322. https://doi.org/10.1016/s0092-8674(00)81662-1 [DOI: 10.1016/s0092-8674(00)81662-1]
  182. Schwinger RH, Bohm M, Schmidt U et al (1995) Unchanged protein levels of SERCA II and phospholamban but reduced Ca uptake and Ca-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92(11):3220–3228. https://doi.org/10.1161/01.cir.92.11.3220 [DOI: 10.1161/01.cir.92.11.3220]
  183. Meyer M, Schillinger W, Pieske B et al (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92(4):778–784. https://doi.org/10.1161/01.cir.92.4.778 [DOI: 10.1161/01.cir.92.4.778]
  184. Takimoto E, Champion HC, Belardi D et al (2005) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96(1):100–109. https://doi.org/10.1161/01.RES.0000152262.22968.72 [DOI: 10.1161/01.RES.0000152262.22968.72]
  185. Mokni W, Keravis T, Etienne-Selloum N et al (2010) Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS ONE 5(12):e14227. https://doi.org/10.1371/journal.pone.0014227 [DOI: 10.1371/journal.pone.0014227]
  186. Pokreisz P, Vandenwijngaert S, Bito V et al (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119(3):408–416. https://doi.org/10.1161/CIRCULATIONAHA.108.822072 [DOI: 10.1161/CIRCULATIONAHA.108.822072]
  187. Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3):238–248. https://doi.org/10.1161/CIRCULATIONAHA.106.655266 [DOI: 10.1161/CIRCULATIONAHA.106.655266]
  188. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB (2012) Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 5(1):79–86. https://doi.org/10.1161/CIRCHEARTFAILURE.111.961706 [DOI: 10.1161/CIRCHEARTFAILURE.111.961706]
  189. Garcia AM, Nakano SJ, Karimpour-Fard A et al (2018) Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro. Circ Heart Fail 11(9):e004571. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004571 [DOI: 10.1161/CIRCHEARTFAILURE.117.004571]
  190. Senzaki H, Smith CJ, Juang GJ et al (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15(10):1718–1726. https://doi.org/10.1096/fj.00-0538com [DOI: 10.1096/fj.00-0538com]
  191. Takimoto E, Champion HC, Li M et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11(2):214–222. https://doi.org/10.1038/nm1175 [DOI: 10.1038/nm1175]
  192. Nakata TM, Suzuki K, Uemura A, Shimada K, Tanaka R (2019) Contrasting effects of Inhibition of phosphodiesterase 3 and 5 on cardiac function and interstitial fibrosis in rats with isoproterenol-induced cardiac dysfunction. J Cardiovasc Pharmacol 73(3):195–205. https://doi.org/10.1097/FJC.0000000000000652 [DOI: 10.1097/FJC.0000000000000652]
  193. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4(1):8–17. https://doi.org/10.1161/CIRCHEARTFAILURE.110.944694 [DOI: 10.1161/CIRCHEARTFAILURE.110.944694]
  194. Soderling SH, Bayuga SJ, Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95(15):8991–8996. https://doi.org/10.1073/pnas.95.15.8991 [DOI: 10.1073/pnas.95.15.8991]
  195. Wang H, Yan Z, Yang S, Cai J, Robinson H, Ke H (2008) Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47(48):12760–12768. https://doi.org/10.1021/bi801487x [DOI: 10.1021/bi801487x]
  196. Patrucco E, Albergine MS, Santana LF, Beavo JA (2010) Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol 49(2):330–333. https://doi.org/10.1016/j.yjmcc.2010.03.016 [DOI: 10.1016/j.yjmcc.2010.03.016]
  197. Methawasin M, Strom J, Borkowski T et al (2020) Phosphodiesterase 9a Inhibition in mouse models of diastolic dysfunction. Circ Heart Fail 13(5):e006609. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006609 [DOI: 10.1161/CIRCHEARTFAILURE.119.006609]
  198. Scott NJA, Rademaker MT, Charles CJ, Espiner EA, Richards AM (2019) Hemodynamic, hormonal, and renal actions of phosphodiesterase-9 inhibition in experimental heart failure. J Am Coll Cardiol 74(7):889–901. https://doi.org/10.1016/j.jacc.2019.05.067 [DOI: 10.1016/j.jacc.2019.05.067]
  199. Chen S, Zhang Y, Lighthouse JK et al (2020) A novel role of cyclic nucleotide phosphodiesterase 10A in pathological cardiac remodeling and dysfunction. Circulation 141(3):217–233. https://doi.org/10.1161/CIRCULATIONAHA.119.042178 [DOI: 10.1161/CIRCULATIONAHA.119.042178]
  200. Hall DD, Feekes JA, Arachchige Don AS et al (2006) Binding of protein phosphatase 2A to the L-type calcium channel Cav1.2 next to Ser1928, its main PKA site, is critical for Ser1928 dephosphorylation. Biochemistry 45(10):3448–3459. https://doi.org/10.1021/bi051593z [DOI: 10.1021/bi051593z]
  201. El Refaey M, Musa H, Murphy NP et al (2019) Protein phosphatase 2A regulates cardiac Na(+) channels. Circ Res 124(5):737–746. https://doi.org/10.1161/CIRCRESAHA.118.314350 [DOI: 10.1161/CIRCRESAHA.118.314350]
  202. Lubelwana Hafver T, Wanichawan P, Manfra O et al (2017) Mapping the in vitro interactome of cardiac sodium Na+-calcium Ca exchanger 1 (NCX1). Proteomics 17:17–18. https://doi.org/10.1002/pmic.201600417 [DOI: 10.1002/pmic.201600417]
  203. Hua F, Wu Z, Yan X et al (2018) DR region of Na(+)-K(+)-ATPase is a new target to protect heart against oxidative injury. Sci Rep 8(1):13100. https://doi.org/10.1038/s41598-018-31460-z [DOI: 10.1038/s41598-018-31460-z]
  204. Belevych AE, Sansom SE, Terentyeva R et al (2011) MicroRNA-1 and – 133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS ONE 6(12):e28324. https://doi.org/10.1371/journal.pone.0028324 [DOI: 10.1371/journal.pone.0028324]
  205. Terentyev D, Belevych AE, Terentyeva R et al (2009) miR-1 overexpression enhances Ca release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 104(4):514–521. https://doi.org/10.1161/CIRCRESAHA.108.181651 [DOI: 10.1161/CIRCRESAHA.108.181651]
  206. Jideama NM, Crawford BH, Hussain AK, Raynor RL (2006) Dephosphorylation specificities of protein phosphatase for cardiac troponin I, troponin T, and sites within troponin T. Int J Biol Sci 2(1):1–9. https://doi.org/10.7150/ijbs.2.1 [DOI: 10.7150/ijbs.2.1]
  207. Yin X, Cuello F, Mayr U et al (2010) Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distribution. Mol Cell Proteom 9(3):497–509. https://doi.org/10.1074/mcp.M900275-MCP200 [DOI: 10.1074/mcp.M900275-MCP200]
  208. Mumby MC, Russell KL, Garrard LJ, Green DD (1987) Cardiac contractile protein phosphatases. Purification of two enzyme forms and their characterization with subunit-specific antibodies. J Biol Chem 262(13):6257–6265 [DOI: 10.1016/S0021-9258(18)45563-9]
  209. Wu SC, Solaro RJ (2007) Protein kinase C zeta. A novel regulator of both phosphorylation and de-phosphorylation of cardiac sarcomeric proteins. J Biol Chem 282(42):30691–30698. https://doi.org/10.1074/jbc.M703670200 [DOI: 10.1074/jbc.M703670200]
  210. Surks HK, Mochizuki N, Kasai Y et al (1999) Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. Science 286(5444):1583–1587. https://doi.org/10.1126/science.286.5444.1583 [DOI: 10.1126/science.286.5444.1583]
  211. Ravan H, Yazdanparast R (2012) Development of a new loop-mediated isothermal amplification assay for prt (rfbS) gene to improve the identification of salmonella serogroup D. World J Microbiol Biotechnol 28(5):2101–2106. https://doi.org/10.1007/s11274-012-1014-5 [DOI: 10.1007/s11274-012-1014-5]
  212. Cai Z, Wu C, Xu Y, Cai J, Zhao M, Zu L (2023) The NO-cGMP-PKG Axis in HFpEF: from pathological mechanisms to potential therapies. Aging Dis 14(1):46–62. https://doi.org/10.14336/AD.2022.0523 [DOI: 10.14336/AD.2022.0523]
  213. Ladage D, Tilemann L, Ishikawa K et al (2011) Inhibition of PKCalpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res 109(12):1396–1400. https://doi.org/10.1161/CIRCRESAHA.111.255687 [DOI: 10.1161/CIRCRESAHA.111.255687]
  214. Zhang J, Liang R, Wang K et al (2022) Novel CaMKII-delta inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. Circulation 145(15):1154–1168. https://doi.org/10.1161/CIRCULATIONAHA.121.055920 [DOI: 10.1161/CIRCULATIONAHA.121.055920]

Grants

  1. ZR2023QH190/Natural Science Foundation of Shandong Province

MeSH Term

Humans
Heart Failure
Phosphorylation
Calcium
Calcium Channels, L-Type
Endoplasmic Reticulum
Myocardium
Myofibrils

Chemicals

Calcium
Calcium Channels, L-Type
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0phosphorylation/dephosphorylationHFfailureCaLTCCfunctionchangesHeartcanabnormalmyocardialsystolediastolecurrentL-typecalciumchanneldysfunctionreticulumERmyofilamentnormalheartbasedtherapeuticcausedvarietycausescharacterizedmembraneinitialtriggersignalcardiaccycleDeclinedassociateddisordercorrelatedunbalancedlevelsendoplasmicKinasephosphataseactivityalongprogressresultingphaseddegreeimportantrealizedifferencesfailingreviewfocusesprogressionsummarizeseffectsconditionspreviousexperimentsclinicalresearchAlsosummarizemethodsclarifypotentialdirectionsAbnormalCa2+EndoplasmicPhosphorylation

Similar Articles

Cited By